Michael Breen is a Scientist at Tiba Biotech. He joined Tiba after finishing his Ph.D. in Microbiology at Boston University in 2023 where he studied lung-resident B cell populations that arise after influenza virus infection. At Tiba, Michael has initiated multiple therapeutic and vaccine research projects using the company's proprietary RNA delivery platform. His roles range from antigen and RNA payload design to the planning and execution of in vivo experiments to evaluate novel therapies and targeted delivery approaches. As a recent Ph.D. graduate, Michael has also taken part in career panels discussing how to transition from academia into industry as a young scientist.